{"id":688613,"date":"2022-09-26T07:07:13","date_gmt":"2022-09-26T11:07:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-will-present-new-scientific-data-and-analyses-during-the-american-academy-of-ophthalmology-annual-meeting\/"},"modified":"2022-09-26T07:07:13","modified_gmt":"2022-09-26T11:07:13","slug":"bausch-lomb-will-present-new-scientific-data-and-analyses-during-the-american-academy-of-ophthalmology-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bausch-lomb-will-present-new-scientific-data-and-analyses-during-the-american-academy-of-ophthalmology-annual-meeting\/","title":{"rendered":"Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n Bausch + Lomb Will Sponsor Two Educational Events on Dry Eye Disease<\/i>
\n <\/b>\n <\/p>\n

\n
\n VAUGHAN, ON<\/span>
\n <\/span>, Sept. 26, 2022<\/span><\/span> \/PRNewswire\/ — Bausch + Lomb Corporation (NYSE\/TSX: BLCO) (“Bausch + Lomb”), a leading global eye health company dedicated to helping people see better to live better, today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago<\/span> from Sept. 30 to Oct. 3, 2022<\/span>.<\/p>\n

In addition to data from Bausch + Lomb’s ARMOR study, the presentations will include data and analyses on investigational treatment NOV03 (perfluorohexyloctane), investigational biosimilar candidate to LUCENTIS\u00ae<\/sup>*<\/b>\u00a0(ranibizumab)1<\/sup>, ClearVisc\u2122 dispersive ophthalmic viscosurgical device and XIPERE\u00ae<\/sup> (triamcinolone acetonide injectable suspension), which became commercially available in the United States<\/span> earlier this year. Bausch + Lomb will also sponsor two educational events focusing on dry eye disease (DED), one of the most common ocular surface disorders that affects approximately 18 million Americans.2,3<\/sup>\u00a0<\/p>\n

“Every year, AAO provides a tremendous opportunity for physicians and those of us in the ophthalmic industry to connect and exchange information,” said Joseph C. Papa<\/span>, CEO, Bausch + Lomb. “This will be our first time participating in the meeting since becoming a publicly traded company earlier this year, and we are particularly excited to share new research and news about our products and pipeline, and provide valuable educational opportunities for eye care providers.”<\/p>\n

The complete list of scientific paper and poster presentations, as well as details for the sponsored education events is as follows:\u00a0<\/p>\n

\n Podium Presentations<\/b>\n <\/p>\n